Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety, Immunogenicty and Anti-Reservoir Activity of an Electroporation-Administered HIV DNA Vaccine Encoding GAG, POL and ENV Proteins With IL-12 Plasmid in HIV-Infected Adults on Antriretroviral Therapy

Next Previous
Search
Trial Profile

Safety, Immunogenicty and Anti-Reservoir Activity of an Electroporation-Administered HIV DNA Vaccine Encoding GAG, POL and ENV Proteins With IL-12 Plasmid in HIV-Infected Adults on Antriretroviral Therapy

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 02 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs HIV DNA vaccine (Primary) ; INO 9012 (Primary) ; INO-6145 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Pharmacodynamics; Proof of concept
  • Acronyms PENNVAX

Most Recent Events

  • 22 Feb 2023 Results assessing the immunologic signatures, at the cellular and transcriptional level, that correlate with augmented HIV-specific T cell responses post-vaccination in 30 participants with HIV who received an HIV DNA vaccine/IL-12 in the PENNVAX clinical trial, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
  • 22 Feb 2023 Results assessing the virologic outcomes of Gag+Pol+IL-12 DNA (G/P), Gag+Pol+Env+IL-12 DNA (G/P/E) in participants with HIV on suppressive antiretroviral therapy, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023.
  • 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top